Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Glioblastoma 4Neoplasms 3Lymphoma 3Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Glioma 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphoid 1Gliosarcoma 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Brain Neoplasms 1

Interventions

Carboplatin 30Cisplatin 23pembrolizumab 22Paclitaxel 21Pemetrexed 20Gemcitabine 10osimertinib 9durvalumab 9Nivolumab 9130-nm albumin-bound paclitaxel 8Sunitinib 7Sorafenib 7Fluorouracil 7Everolimus 7Docetaxel 7Axitinib 7Cetuximab 6epothilone B 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5volociximab 4trebananib 4reolysin 4catumaxomab 4cabozantinib 4atezolizumab 4Radiotherapy 4Ipilimumab 4vosaroxin 3liposomal doxorubicin 3lenvatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma × enzastaurin × Clear all
NCT00420381 2020-12-19

Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer

Eli Lilly and Company

Phase 2 Completed
28 enrolled 13 charts
Gynecologic

Carcinoma, Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡